Aclaris Q2: $170.6M Cash, Runway Through 2028; Three Key Readouts in H2 2026
ACRS has more than doubled off its 52-week low of $1.52 on elevated volume (3.2× avg).
Summary
Aclaris Therapeutics reported Q2 2026 results with $170.6M in cash, raised an additional $40.2M post-quarter, and extended its runway through 2028. The company reaffirmed timelines for three key clinical readouts in H2 2026 and plans to initiate two Phase 2b programs in Q4.
Key Events · Earnings and Guidance · ACRS
-
Cash Runway Extended Through 2028
Cash, cash equivalents and marketable securities were $170.6 million as of June 30, 2026. Post-quarter ATM sales of 7.3 million shares raised $40.2 million in gross proceeds, extending the expected runway through the end of 2028.
-
Three Key Clinical Readouts in H2 2026
Top-line results expected in the second half of 2026 from two Phase 1b proof-of-concept trials of ATI-052 (asthma and atopic dermatitis) and the Phase 2 trial of bosakitug in atopic dermatitis.
-
Positive Phase 1a Data for ATI-052
Full top-line results from the SAD/MAD trial showed ATI-052 was well tolerated with strong and sustained PK/PD, supporting potential for up to quarterly dosing and best-in-class potency.
-
Phase 2b Initiations Planned for Q4 2026
Aclaris intends to start a Phase 2b trial of ATI-052 in asthma and a Phase 2b trial of modzatinib in lichen planus in the fourth quarter of 2026.
Analysis · ACRS · Life Sciences
Aclaris reported Q2 2026 results with a net loss of $21.5 million and $170.6 million in cash as of June 30. After the quarter, the company raised an additional $40.2 million through ATM sales, extending its cash runway through the end of 2028 — a critical survival signal for a clinical-stage biotech. The pipeline update is packed with near-term catalysts: three placebo-controlled data readouts in the second half of 2026 (ATI-052 Phase 1b in asthma and atopic dermatitis, bosakitug Phase 2 in atopic dermatitis), plus Phase 2b initiations for ATI-052 and modzatinib in Q4. Positive Phase 1a data for ATI-052 supports best-in-class potency and quarterly dosing, raising the stakes for the upcoming POC results. The combination of a strengthened balance sheet and a catalyst-rich second half makes this a notable update for investors.
At the time of this filing, ACRS was trading at $6.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $888.3M. The 52-week trading range was $1.52 to $6.52. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.